VITAL KSK HOLDINGS,INC. (3151) Stock Price

Vital KSK Holdings operates four main business segments: pharmaceutical wholesale, pharmacy operations, veterinary pharmaceutical wholesale, and other businesses. These operations are conducted through the company, 18 subsidiaries, and 5 affiliated companies.

In the pharmaceutical wholesale segment, affiliated companies including Vitalnet, KSK, and Fines distribute pharmaceuticals to medical institutions and pharmacies, supporting healthcare delivery.

In the pharmacy segment, companies such as Oono, Good Neighbor, Kenkoudo Pharmacy, and Tenno Health Dispensing Center operate community-based pharmacies. These provide pharmaceuticals and health consultations to local residents.

In the veterinary pharmaceutical wholesale segment, Agro Japan and Arrow Medical handle the distribution of veterinary pharmaceuticals, supporting health management in livestock and pet industries.

In other businesses, companies including Medical Management Research Institute, Vital Green, and Vital Care operate diverse services including pharmaceutical retail, agricultural chemical wholesale, transportation, nursing care services, and healthcare consulting. This enables the company to provide services across a wide range of sectors.

Vital KSK Holdings aims to support regional healthcare by accelerating management speed and strengthening market development. The company seeks to enhance profitability by integrating IT technology with pharmaceutical distribution technology and leveraging synergies.

Under its Long-Term Vision 2035, the company targets pharmaceutical wholesale business to represent 80% of sales and healthcare-related businesses to represent 20%. For operating profit, the targets are 60% from pharmaceutical wholesale and 40% from healthcare-related businesses.

The Medium-Term Management Plan 2027 targets sales of 660 billion yen, a core operating profit margin of 1.15% or higher, and an adjusted ROE of 8.0% or higher. The company plans to invest 200 billion yen while maintaining disciplined balance sheet management with a focus on capital efficiency.

The company has decided to enter the pharmaceutical manufacturing business and is advancing logistics optimization and pharmaceutical wholesale business transformation. It is also expanding medical-related product offerings, strengthening rental operations, and enhancing partnerships with government and local authorities to develop life support services.

The Medium-Term Management Plan 2027 prioritizes business portfolio management, financial strategy and capital policy, and strengthening group management structure. These initiatives aim to achieve sustainable growth and enhance long-term corporate value.